Japan Needle Free Injections Market Outlook to 2023

Japan Needle Free Injections Market Outlook to 2023


  • Products Id :- GDMECC2547DB
  • |
  • Pages: 30
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Japan Needle Free Injections Market Outlook to 2023

Summary

GlobalData's new report, "Japan Needle Free Injections Market Outlook to 2023", provides key market data on the Japan Needle Free Injections market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Needle Free Injections.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

Market size and company share data for Needle Free Injections.

Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.

2016 company shares and distribution shares data for each of the market segments.

Global corporate-level profiles of key companies operating within the Japan Needle Free Injections market.

Key players covered include INJEX-Equidyne Systems, Bioject Medical Technologies Inc and Antares Pharma Inc.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.

Develop market-entry and market expansion strategies.

Design competition strategies by identifying who-stands-where in the market.

Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 What Is This Report About? 5

2.2 Needle Free Injections Market Segmentation 5

2.3 Definitions of Markets Covered in the Report 6

3 Needle Free Injections Market, Japan 7

3.1 Needle Free Injections Market, Japan, Revenue ($m), 2009-2016 7

3.2 Needle Free Injections Market, Japan, Revenue ($m), 2016-2023 8

3.3 Needle Free Injections Market, Japan, Volume (Units), 2009-2016 9

3.4 Needle Free Injections Market, Japan, Volume (Units), 2016-2023 10

3.5 Needle Free Injections Market, Japan, Average Price ($), 2009-2023 11

3.6 Needle Free Injections Market, Japan, Distribution Share by Revenue ($m), 2015-2016 12

3.7 Needle Free Injections Market, Japan, Company Share by Revenue ($m), 2016 13

4 Overview of Key Companies in Japan, Needle Free Injections Market 15

4.1 Bioject Medical Technologies Inc 15

4.1.1 Company Overview 15

4.2 INJEX-Equidyne Systems 15

4.2.1 Company Overview 15

4.3 Antares Pharma Inc 15

4.3.1 Company Overview 15

4.4 MK Global Co. 15

4.4.1 Company Overview 15

4.5 The European Pharma Group 15

4.5.1 Company Overview 15

5 Needle Free Injections Market Pipeline Products 16

6 Financial Deals Landscape 17

6.1 Debt Offerings 17

6.1.1 Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 17

6.1.2 Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 18

7 Recent Developments 19

7.1 Corporate Communications 19

7.1.1 Feb 24, 2017: Daiichi Sankyo Appoints New Group Corporate Officers 19

7.1.2 Feb 09, 2017: Terumo Announces Change of Executive Officers 19

7.1.3 Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 20

7.1.4 Sep 06, 2016: Daiichi Sankyo Announces New Global Head of Development 20

7.2 Government and Public Interest 21

7.2.1 Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 21

7.3 Other Significant Developments 21

7.3.1 Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 21

7.3.2 Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research Development System 22

7.3.3 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 22

7.4 Strategy And Business Planning 23

7.4.1 Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 23

7.4.2 Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 23

7.4.3 Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research Development Structure 24

7.4.4 Jan 31, 2017: Terumo Opens a Branch in Yangon 24

8 Appendix 26

8.1 Research Methodology 27

8.1.1 Coverage 27

8.1.2 Secondary Research 27

8.1.3 Primary Research 28

8.1.4 Company Share Analysis 28

8.1.5 Distribution Share Analysis 28

8.1.6 Benchmarking 29

8.2 GlobalData Consulting 29

8.3 Contact Us 30

8.4 Disclaimer 30

1.2 List of Figures

Figure 1: Needle Free Injections Market, Japan, Revenue ($m), USD Constant, Historic, 2009-2016 7

Figure 2: Needle Free Injections Market, Japan, Revenue ($m), USD Constant, Forecast, 2016-2023 8

Figure 3: Needle Free Injections Market, Japan, Volume (Units), Historic, 2009-2016 9

Figure 4: Needle Free Injections Market, Japan, Volume (Units), Forecast, 2016-2023 10

Figure 5: Needle Free Injections Market, Japan, Company Share (%) 2016 13

1.1 List of Tables

Table 1: Needle Free Injections Market, Japan, Revenue ($m), USD Constant, Historic, 2009-2016 7

Table 2: Needle Free Injections Market, Japan, Revenue ($m), USD Constant, Forecast, 2016-2023 8

Table 3: Needle Free Injections Market, Japan, Volume (Units), Historic, 2009-2016 9

Table 4: Needle Free Injections Market, Japan, Volume (Units), Forecast, 2016-2023 10

Table 5: Needle Free Injections Market, Japan, Average Price ($), Historic, 2009-2016 11

Table 6: Needle Free Injections Market, Japan, Average Price ($), Forecast, 2016-2023 11

Table 7: Needle Free Injections Market, Japan, Distribution Share by Revenue ($m), USD Constant, 2015-2016 12

Table 8: Needle Free Injections Market, Japan, Company Share by Revenue ($m), USD Constant, 2016 14

Table 9: Needle Free Injections Market Pipeline Products 16

Table 10: Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 17

Table 11: Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bioject Medical Technologies Inc

INJEX-Equidyne Systems

Antares Pharma Inc

MK Global Co.

The European Pharma Group

Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd

select a license
Single User License
USD 4995 INR 349650
Site License
USD 9990 INR 699300
Corporate User License
USD 14985 INR 1048950

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com